Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

0

Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously reported on June 19, 2015, Richard P. Shea, the then-current Chief Financial Officer (“CFO”) of Momenta Pharmaceuticals, Inc. (the “Company”) notified the Company of his intention to resign as CFO upon the Company’s identification and appointment of a successor CFO.  As previously reported on November 2, 2016, the Company appointed Scott M. Storer as its Senior Vice President, Chief Financial Officer, commencing November 28, 2016. As part of the previously disclosed CFO succession plan developed by Mr. Shea and the Company, Mr. Shea remained an employee with the Company through December 30, 2016 to assist with the transition to a new CFO. On December 30, 2016, the Company entered into a consulting agreement with Mr. Shea to provide post-retirement consulting and advisory services to the Company in connection with the CFO transition (the “Consulting Agreement”). The terms of the Consulting Agreement were approved by the independent members of the Company’s Board of Directors.

The term of the Consulting Agreement is six months, beginning December 30, 2016. During the term, Mr. Shea has agreed, at the request of the Company, to advise and assist on, among other things, financial reporting, investor relations and facilities-related matters. Mr. Shea is entitled to receive an hourly fee for services rendered, up to a maximum aggregate amount of $100,000, as well as reasonable travel and other expenses incurred by him in rendering his services. Also to the Consulting Agreement, in recognition of his contributions to the Company throughout 2016, Mr. Shea is also entitled to receive a one-time cash payment of $159,830, payable on March 31, 2017, provided that Mr. Shea has not terminated the Consulting Agreement or the Company has not terminated the Consulting Agreement for cause (as defined in the Consulting Agreement), in each case prior to March 31, 2017. The amount of the one-time cash payment is equal to Mr. Shea’s 2016 employee target cash bonus, for which we would have been eligible had he been an employee of the Company when 2016 employee bonuses are paid, generally in early 2017.


About Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Recent Trading Information

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) closed its last trading session up +0.05 at 15.05 with 254,940 shares trading hands.